The advent of immunotherapy has transformed dermatologic care, offering hope to patients with advanced NMSC. As the treatment armamentarium expands, clinicians must carefully weigh evolving data in order to optimize outcomes in BCC and CSCC.
Join us for this live webstream to hear our interprofessional expert panel offer privileged insights into evidence-based strategies for the identification of high-risk disease, selection of checkpoint inhibitors, and the management of immune-related adverse events. Uniquely, this panel discussion also features an experienced patient who will augment these insights with teaching moments from their treatment journey.
Upon completion of this activity, participants should be better able to:
Director, Cutaneous Oncology, GW Cancer Center
Director, Dermatologic Surgery, GW Department of Dermatology
Assistant Professor, Dermatology & Hematology/Oncology
Washington, DC
Medical Oncologist, Dermatologist
Massachusetts General Hospital
Director, Center for Merkel Cell Carcinoma
Co-Director, NMSC Multi-Disciplinary Clinic
Department of Medicine, Division of Hematology/Oncology
Department of Dermatology
Massachusetts General Cancer Center
Boston, MA
Nurse Practitioner, Center for Melanoma
Massachusetts General Hospital
Boston, MA
Featured RMEI CE Activities
Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources
